We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Moderna is following up on the success of its messenger RNA-based COVID-19 vaccine with plans to develop inoculations for numerous other infectious diseases, the company said Monday. Read More
COVID-19 patients on intensive care support did not see improvement when given convalescent plasma, according to preliminary findings from the UK arm of a global trial. Read More
Pfizer and BioNTech now anticipate manufacturing up to 2 billion doses of their highly effective COVID-19 vaccine by the end of the year as vaccination efforts ramp up and demand for shots increases around the globe. Read More
A phase 2 trial of Eli Lilly’s investigational Alzheimer’s drug donanemab demonstrated a “significant slowing of decline” in early Alzheimer’s patients who exhibited symptoms, the company revealed Monday. Read More
Pfizer/BioNTech’s COVID-19 vaccine should ideally be given in two doses 21 to 28 days apart, but due to ongoing shortages, an interval of up to 42 days is acceptable, the World Health Organization (WHO) said Friday. Read More
The European Union has secured 200 million more doses of the Pfizer/BioNTech COVID-19 vaccine, with an option to buy 100 million additional doses, bringing the total number of potential doses contracted for to 600 million. Read More